search
Back to results

EA for PAAS: A pRCT

Primary Purpose

Substance Withdrawal Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Electro-Acupuncture
Sponsored by
Chengdu University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Substance Withdrawal Syndrome

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients meet the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (21);
  • A urine test for methamphetamine is negative.
  • 18-60 years old, male or female, conscious, no aphasia, or mental retardation, primary school education or above, and able to understand the contents of the scales and cooperate with treatment;
  • Did not participate in other clinical trials within 3 months;
  • Signed the informed consent from.

Exclusion Criteria:

  • Local trauma or infected persons who have received EA;
  • Can' not tolerate EA, EA treatment, or allergic to EA needles;
  • Pregnant or breastfeeding women;
  • Serious disorders of the heart, liver, or kidney, or suicidal tendencies.

Sites / Locations

  • Affliated Hospital of Chengdu University of Traditional Chinese MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Electro-Acupuncture group

Wait-list group

Arm Description

The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.

We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.

Outcomes

Primary Outcome Measures

Amphetamine Cessation Symptom Assessment
It consists of three subscales, namely, "anxiety and mood", "fatigue", and "craving". Items are scored on a five-point scale ranging from 0 to 4 with higher scores representing more severe Amphetamine Cessation Symptom

Secondary Outcome Measures

Visual Analog Scale
Determining the craving for amphetamine.The scores is from 0 to 10, and the higher scores means the more craving for amphetamine.
Hamilton Depression Scale
Assessment for depression.And the interpretation of HAMD scores is as follows: <7, no depression; 7-17, mild depression; 17-24, moderate depression; and >24, severe depression.
Hamilton Anxiety Scale
Assessment for anxiety. And the interpretation of HAMA scores is as follows: <7, no anxiety;7-14, mild anxiety; 14-20, moderate anxiety; 21-28, severe anxiety; and >29, extremely severe anxiety.
Pittsburgh Sleep Quality Index
The scores are from 0 to 21.Higher scores reflect worse sleep quality.
36-item Short Form Health Survey
This questionnaire contains 9 parts: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health and Reported Health Transition.

Full Information

First Posted
May 26, 2021
Last Updated
June 7, 2021
Sponsor
Chengdu University of Traditional Chinese Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT04917185
Brief Title
EA for PAAS: A pRCT
Official Title
Electro-acupuncture for Protracted Amphetamine Abstinence Syndrome : A Pragmatic Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Recruiting
Study Start Date
June 2021 (Anticipated)
Primary Completion Date
July 2022 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chengdu University of Traditional Chinese Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
In 2019, around 27 million people worldwide, corresponding to 0.5% of the adult population, have used amphetamine-type stimulants (ATS). More than one-third of these 27 million users of ATS were in East and South-East Asia. ATS are a group of synthetic psychostimulants including methamphetamine, amphetamine, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and related substances. Although the biology underlying amphetamine withdrawal syndrome is not fully understood, amphetamine has been shown to produce long-lasting reductions in neuronal expression of dopamine neuronal markers. Abuse of these synthetic psychostimulants can lead to drug addiction, and subsequent withdrawal can cause a series of mental symptoms, such as anxiety, depression, confusion, insomnia, mood disturbances, cognitive impairments, and delusions. Some studies have shown two clear stages of ATS withdrawal syndrome: an acute phase lasting 7-10 days, and a subacute phase lasting a further 2 weeks or more, which is termed called "Protracted amphetamine abstinence syndrome (PAAS)". The relevant literature has indicated that the majority of patients with ATS withdrawal disorders can experience depression, cognitive impairments, insomnia, and anxiety, especially during the PAAS stage. These symptoms may affect the treatment and finally lead to a relapse. Nowadays, pharmacological therapies are mostly symptom-targeted and show an ungratified effectiveness for amphetamine-type drugs. There is no a medication approved by Food and Drug Administration for use in the treatment of methamphetamine addiction. Therefore, the treatment of PAAS is essential for the treatment of ATS use disorders. Traditional Chinese medicine (TCM), especially acupuncture, is effective in the treatment of withdrawal symptoms with few side effects. research on acupuncture detoxification originates from the treatment of opioid drug withdrawal. Studies have shown that acupuncture has high efficacy in the treatment of protracted abstinence symptoms after heroin addiction. This study hypothesizes that acupuncture has the same mechanism of action in the treatment of PAAS as in the treatment of protracted opioid abstinence syndrome. Therefore, investigators have designed a real-world-based pragmatic randomized controlled trial (pRCT) to determine the effectiveness of acupuncture in the treatment of PAAS and provide support for clinical decision-making. Investigators conduct a pragmatic randomized controlled trials(pRCT) to observe the effect of acupuncture in a larger sample. It combines the advantages of randomization and real-world data, and the results can provide the best real-world evidence for the assessment of intervention effects or comparative effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Substance Withdrawal Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Electro-Acupuncture group
Arm Type
Experimental
Arm Description
The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
Arm Title
Wait-list group
Arm Type
No Intervention
Arm Description
We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
Intervention Type
Other
Intervention Name(s)
Electro-Acupuncture
Intervention Description
Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
Primary Outcome Measure Information:
Title
Amphetamine Cessation Symptom Assessment
Description
It consists of three subscales, namely, "anxiety and mood", "fatigue", and "craving". Items are scored on a five-point scale ranging from 0 to 4 with higher scores representing more severe Amphetamine Cessation Symptom
Time Frame
Change from baseline Amphetamine Cessation Symptom Assessment scores at 1 month.
Secondary Outcome Measure Information:
Title
Visual Analog Scale
Description
Determining the craving for amphetamine.The scores is from 0 to 10, and the higher scores means the more craving for amphetamine.
Time Frame
Change from baseline Visual Analog Scale scores at 1 month.
Title
Hamilton Depression Scale
Description
Assessment for depression.And the interpretation of HAMD scores is as follows: <7, no depression; 7-17, mild depression; 17-24, moderate depression; and >24, severe depression.
Time Frame
Change from baseline Hamilton Depression Scale scores at 1 month.
Title
Hamilton Anxiety Scale
Description
Assessment for anxiety. And the interpretation of HAMA scores is as follows: <7, no anxiety;7-14, mild anxiety; 14-20, moderate anxiety; 21-28, severe anxiety; and >29, extremely severe anxiety.
Time Frame
Change from baseline Hamilton Anxiety Scale scores at 1 month.
Title
Pittsburgh Sleep Quality Index
Description
The scores are from 0 to 21.Higher scores reflect worse sleep quality.
Time Frame
Change from baseline Pittsburgh Sleep Quality Index scores at 1 month.
Title
36-item Short Form Health Survey
Description
This questionnaire contains 9 parts: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health and Reported Health Transition.
Time Frame
Change from baseline 36-item Short Form Health Survey scores at 1 month.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients meet the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (21); A urine test for methamphetamine is negative. 18-60 years old, male or female, conscious, no aphasia, or mental retardation, primary school education or above, and able to understand the contents of the scales and cooperate with treatment; Did not participate in other clinical trials within 3 months; Signed the informed consent from. Exclusion Criteria: Local trauma or infected persons who have received EA; Can' not tolerate EA, EA treatment, or allergic to EA needles; Pregnant or breastfeeding women; Serious disorders of the heart, liver, or kidney, or suicidal tendencies.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yulan Ren, PhD
Phone
0086 13689098226
Email
renxg2468@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yiwei Zeng, M.D
Phone
0086 18011566243
Email
YiWei_Zeng@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yulan Ren, PhD
Organizational Affiliation
Chengdu University of Traditional Chinese Medicine
Official's Role
Study Chair
Facility Information:
Facility Name
Affliated Hospital of Chengdu University of Traditional Chinese Medicine
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610072
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Binbin Wu, Doctor
Phone
0086-18190061169
Email
9025340@qq.com

12. IPD Sharing Statement

Learn more about this trial

EA for PAAS: A pRCT

We'll reach out to this number within 24 hrs